Vericel on Track for Robust Second Half in 2021

Vericel's MACI orthobiologic

Vericel reported 2Q21 orthopedic revenue of $26.5 million, +75.6% vs, 2Q19. Compared to the same period for 2019, the company's MACI revenue grew +27.4%. Vericel reiterated its full-year guidance for MACI, with 2021 growth in the mid-30% range.

In the first half of 2021, MACI biopsies grew more than 50% compared to the same time frame last...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us